A095700 Stock Overview
Genexine, Inc., together with its subsidiaries, operates as a biotechnology company that focuses on the development and commercialization of immunotherapies in South Korea and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Genexine, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩7,270.00 |
| 52 Week High | ₩13,480.00 |
| 52 Week Low | ₩6,840.00 |
| Beta | 0.92 |
| 1 Month Change | -20.20% |
| 3 Month Change | -18.04% |
| 1 Year Change | -39.62% |
| 3 Year Change | -92.19% |
| 5 Year Change | -87.37% |
| Change since IPO | -30.25% |
Recent News & Updates
Shareholder Returns
| A095700 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 5.1% | -4.0% | -3.3% |
| 1Y | -39.6% | 0.7% | 1.2% |
Return vs Industry: A095700 underperformed the KR Biotechs industry which returned 0.7% over the past year.
Return vs Market: A095700 underperformed the KR Market which returned 1.2% over the past year.
Price Volatility
| A095700 volatility | |
|---|---|
| A095700 Average Weekly Movement | 5.6% |
| Biotechs Industry Average Movement | 8.2% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 11.9% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A095700's share price has been volatile over the past 3 months.
Volatility Over Time: A095700's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 98 | n/a | www.genexine.com |
Genexine, Inc., together with its subsidiaries, operates as a biotechnology company that focuses on the development and commercialization of immunotherapies in South Korea and internationally. The company develops its products through its hybrid Fc platform, a proprietary technology designed to develop long-acting protein drugs; and the DNA vaccine platform that is used to elicit immune responses in the human body to fight viral infection and cancer cells. Its product pipeline includes GX-H9, which is in Phase II and III clinical trials for the treatment of adult and pediatric growth hormone deficiency; GX-E4 that is in Phase III clinical trials for the treatment of anemia; GX-G3, which is in Phase II clinical trials to treat neutropenia; GX-I7, a product candidate in Phase I and II clinical trials to treat solid tumors, lymphopenia, and COVID-19; GX-P1, which is in Phase I clinical trials for the treatment of autoimmune diseases and transplantation; and GX-G6 that is in Phase II clinical trials for the treatment of diabetes.
Genexine, Inc. Fundamentals Summary
| A095700 fundamental statistics | |
|---|---|
| Market cap | ₩301.34b |
| Earnings (TTM) | -₩66.87b |
| Revenue (TTM) | ₩4.43b |
68.1x
P/S Ratio-4.5x
P/E RatioIs A095700 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A095700 income statement (TTM) | |
|---|---|
| Revenue | ₩4.43b |
| Cost of Revenue | ₩4.12b |
| Gross Profit | ₩302.04m |
| Other Expenses | ₩67.18b |
| Earnings | -₩66.87b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.61k |
| Gross Margin | 6.82% |
| Net Profit Margin | -1,510.71% |
| Debt/Equity Ratio | 22.7% |
How did A095700 perform over the long term?
See historical performance and comparison